FINWIRES · TerminalLIVE
FINWIRES

Research Alert: Hexcel Posts Q1 Beat On Top And Bottom Lines, Strong Margin Expansion

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

HXL posted Q1 adjusted EPS of $0.59 vs. $0.37 prior year, $0.15 above consensus, on sales of $501.5M (+9.9% Y/Y), beating consensus by $18M. Commercial Aerospace sales rose 18.8% Y/Y to $332.7M, led by A350, A320neo, 787, and 737 MAX programs as destocking pressures abated. The results validate our multiyear thesis on operating leverage, with 59.5% EPS growth on sub-10% sales growth as volumes recover into existing capacity. Management reaffirmed 2026 guidance for sales of $2.0B-$2.1B and adjusted EPS of $2.10-$2.30 despite geopolitical uncertainties. Adjusted operating margin expanded 360 bps Y/Y to 13.5%, demonstrating substantial fixed cost leverage. We believe HXL is well positioned to capture incremental revenue from sole-source contracts without material capacity additions, with line of sight to mid-30s incremental margins through 2027, though sustained progress remains contingent on OEM execution and supply chain stability.

Related Articles

Asia

Victory Giant Technology Nets HK$3 Billion From Full Exercise of IPO Over-Allotment Option

Victory Giant Technology (HKG:2476, SHE:300476) said the overallotment option of its Hong Kong initial public offering was fully exercised on Wednesday, according to a same-day Hong Kong bourse filing.The China-based printed circuit board manufacturer expects to raise about HK$3 billion in additional net proceeds.The exercise involved the issue of 14.4 million additional shares at HK$209.88 each, representing about 15% of the total offer shares available under the global offering.Dealings in the over-allotment shares are expected to begin on April 27, the filing said.

$HKG:2476$SHE:300476
Asia

Arovella Therapeutics Says Requisitioning Shareholder Withdraws Notice, Shares Fall 3%

Arovella Therapeutics (ASX:ALA) said the requisitioning shareholder has withdrawn its April 8 notice, which called for a general meeting to appoint three directors, according to a Thursday Australian bourse filing.Arovella Therapeutics had earlier said the notice "cannot be lawfully effected at a general meeting," and had invited the shareholder to formally withdraw the notice.Its shares fell 3% in recent trading on Thursday.

$ASX:ALA
Asia

Lantian Tech's 2025 Profit Slips 3%, Revenue Rises 5%

CETC Lantian Technology's (SHA:688818) net profit attributable to shareholders in 2025 slipped 3% to 327.1 million yuan from 337.2 million yuan a year earlier, according to a Shanghai bourse filing on Thursday.Earnings per share fell 4.5% year on year to 0.21 yuan from 0.22 yuan.Operating revenue rose 5.1% to 3.29 billion yuan from 3.13 billion yuan in the previous year.

$SHA:688818